Advancing Development of Novel Immunotherapy for Chemotherapy-induced Peripheral Neuropathy (CIPN)

推进化疗引起的周围神经病变 (CIPN) 的新型免疫疗法的发展

基本信息

  • 批准号:
    10588384
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

The opioid crisis has emphasized the need for better non-addictive therapeutics for pain management. The chemotherapy-induced peripheral neuropathy (CIPN) imposed on approximately half of patients receiving oxaliplatin treatment for cancer is a significant additional burden. While sophisticated molecular tools are now being introduced to attack cancer and despite severe adverse effects, oxaliplatin chemotherapy remains in wide usage as a primary treatment response at many sites. Its high prevalence of neurotoxicity often limits chemotherapeutic dosing efficacy and maximum therapeutic effect. Patients can experience disabling cold and mechanical hypersensitivity that persist for years after treatment. The toxic effects can cause premature termination of treatment, impacting quality of life and survivability. CIPN can lead to permanent symptoms and disability in up to 40% of cancer survivors subsequently, thus the societal loss in dollars is inestimable. There are no drugs preventing development of CIPN, and CIPN has a poor therapeutic response to analgesics. Our current collaborative effort focuses on optimizing a small molecule single chain Fragment variable antibody (scFv) therapy that reverses chronic neuropathic pain. Smaller engineered scFvs (25-28 kDa) feature similar binding activity but stronger tissue and brain penetrability. These small molecules are considered suitable drug candidates for pain control since they satisfy key parameters such as (1) high affinity for the therapeutic target, (2) high thermostability, (3) lack of aggregation, and (4) availability from high expression cell lines. Commercial viability is dependent on humanization and affinity purification of the current patent pending small brain penetrant scFv therapy effective in murine models. The objective of this proposal is to humanize the current small scFv antibody and while maintaining more than 50% effectiveness in the murine CIPN pain model. The methodology used will be to ascertain the minimum requirements for humanization, affinity maturation, and then to bench test the antibody for effectiveness in the CIPN model vivo and in in vitro models including human-like neurons, expression systems, and primary sensory neurons from CIPN mice to validate feasibility for continuing with human clinical trials. Finally, we will seek independent commercial confirmation to demonstrate safety with PK/PD, distribution, and toxicology validation studies. The ultimate objective of this project is realization of an effective and commercially viable non-opioid treatment for chemotherapy induced neuropathic pain (CINP). The single chain Fragment variable (scFv) antibody therapy designed would prevent CINP and/or mitigate long standing, disabling CINP.
阿片类药物危机强调需要更好的非成瘾疗法来治疗疼痛。这 大约一半接受化疗的患者会出现化疗引起的周围神经病变(CIPN) 奥沙利铂治疗癌症是一个重大的额外负担。虽然现在已经有了先进的分子工具 奥沙利铂被用于治疗癌症,尽管有严重的副作用,但奥沙利铂化疗仍然广泛使用 在许多地点用作主要治疗反应。其神经毒性的高患病率通常限制了 化疗剂量功效和最大治疗效果。患者可能会经历致残的感冒和 治疗后持续数年的机械过敏。毒性作用可能导致早产 终止治疗,影响生活质量和生存能力。 CIPN 可导致永久性症状 随后高达 40% 的癌症幸存者残疾,因此社会损失无法估量。那里 没有药物可以预防 CIPN 的发生,并且 CIPN 对镇痛药的治疗反应较差。我们的 目前的合作重点是优化小分子单链片段可变抗体 (scFv)疗法可逆转慢性神经性疼痛。较小的工程化 scFv (25-28 kDa) 具有相似的特性 结合活性强,但组织和脑的穿透性更强。这些小分子被认为是合适的药物 疼痛控制的候选者,因为它们满足关键参数,例如(1)对治疗靶点的高亲和力, (2) 高热稳定性,(3) 缺乏聚集,以及 (4) 来自高表达细胞系的可用性。商业的 可行性取决于当前正在申请专利的小脑渗透剂的人源化和亲和纯化 scFv 疗法在小鼠模型中有效。该提案的目的是使当前的小型 scFv 人性化 抗体,同时在小鼠 CIPN 疼痛模型中保持 50% 以上的有效性。方法论 用于确定人源化、亲和力成熟的最低要求,然后进行基准测试 抗体在CIPN体内模型和体外模型(包括类人神经元)中的有效性, 表达系统和 CIPN 小鼠的初级感觉神经元,以验证继续进行的可行性 人体临床试验。最后,我们将寻求独立的商业确认以证明安全性 PK/PD、分布和毒理学验证研究。该项目的最终目标是实现 有效且商业上可行的非阿片类药物治疗化疗引起的神经性疼痛(CINP)。这 单链片段可变 (scFv) 抗体疗法旨在预防 CINP 和/或减轻长期 站立,禁用 CINP。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KARIN N. WESTLUND-HIGH其他文献

KARIN N. WESTLUND-HIGH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KARIN N. WESTLUND-HIGH', 18)}}的其他基金

ShEEP Request for Biotek Cytation 5 Imaging System
ShEEP 请求 Biotek Cytation 5 成像系统
  • 批准号:
    10175798
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Modulating Pain Generators of Chronic Trigeminal Neuropathic Pain
调节慢性三叉神经病理性疼痛的疼痛发生器
  • 批准号:
    10513813
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Peripheral and Central Pain Generators of Chronic Trigeminal Neuropathic Pain
慢性三叉神经病理性疼痛的周围和中枢疼痛发生器
  • 批准号:
    9031396
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Modulating Pain Generators of Chronic Trigeminal Neuropathic Pain
调节慢性三叉神经病理性疼痛的疼痛发生器
  • 批准号:
    10293538
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Modulating Pain Generators of Chronic Trigeminal Neuropathic Pain
调节慢性三叉神经病理性疼痛的疼痛发生器
  • 批准号:
    10012520
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Physiological and Emotional Reactivity to Pain after Physical and Sexual Abuse
身体和性虐待后对疼痛的生理和情感反应
  • 批准号:
    8214456
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Glutamate Induced Molecular Events Contributing to Chro*
谷氨酸诱导的分子事件有助于 Chro*
  • 批准号:
    6533040
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:
Glutamate Induced Molecular Events
谷氨酸诱导的分子事件
  • 批准号:
    6440349
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:
Neurogeneic Amplification of Pancreatitis Pain
胰腺炎疼痛的神经源性放大
  • 批准号:
    7871859
  • 财政年份:
    2000
  • 资助金额:
    --
  • 项目类别:
Neurogenic Amplification of Pancreatitis Pain
胰腺炎疼痛的神经源性放大
  • 批准号:
    8288067
  • 财政年份:
    2000
  • 资助金额:
    --
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了